Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
AstraZeneca PLC - Cambridge, England-based drugmaker - Says Lynparza treatment has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, who have already been treated with chemotherapy either before or after surgery.
Read more(Alliance News) - Hutchmed (China) Ltd on Monday said it has received USD15 million from AstraZeneca PLC as start-up activities for Saffron commenced.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday afternoon:
Read more
March 1 (Reuters) - European stocks tumbled on Tuesday, kicking off March on a dour note on weak earnings reports and jitters over the Ukraine crisis as Russia raged on with its attack after ceasefire talks between the two nations failed to reach a breakthrough.
Read moreMarch 1 (Reuters) - London's FTSE 100 fell on Tuesday as the worsening Ukraine crisis pushed shares of heavyweight banking and Russia-exposed miners lower, while Flutter Entertainment dropped on downbeat earnings.
Read more(Alliance News) - AstraZeneca PLC said on Tuesday its rare disease group has closed an exclusive global collaboration to develop and commercialise an investigational human monoclonal antibody.
Read more(Alliance News) - Stock prices in London opened lower on Tuesday amid rising concerns over Russia's attack on Ukraine.
Read more
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its rare diseases subsidiary had closed an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development.
Read more(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its rare diseases subsidiary had closed an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:
Read morePARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.
Read morePARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.
Read moreBRUSSELS/LONDON, Feb 23 (Reuters) - The global project to share COVID-19 vaccines is struggling to place more than 300 million doses in the latest sign the problem with vaccinating the world is now more about demand than supply.
Read moreFeb 22 (Reuters) - A large study into rare blood clots linked with AstraZeneca's COVID-19 vaccine found between just one and three cases per million, and only after the first dose, shedding fresh light on the side-effects from the shot.
Read moreFeb 22 (Reuters) - London's FTSE 100 stock index closed higher on Tuesday, recouping earlier losses as strong results from medical products maker Smith+Nephew and gains in industrial stocks countered concerns relating to the Russia-Ukraine crisis.
Read more
Last checked at